ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Relative Exchangeable and Exchangeable Copper: Emerging New Biomarkers for Diagnosis and Therapy Monitoring in Wilson's Disease.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relative Exchangeable and Exchangeable Copper: Emerging New Biomarkers for Diagnosis and Therapy Monitoring in Wilson's Disease.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimsWilson's disease (WD) is a genetic disorder of copper metabolism in which early diagnosis remains challenging, particularly in acute liver failure (ALF). Relative exchangeable copper (REC) and exchangeable copper (CuEXC) are emerging biomarkers for diagnosis and monitoring, but data from larger cohorts are limited. This monocentric retrospective cohort study evaluated the diagnostic accuracy of REC in WD patients, including adult ALF and assessed the utility of CuEXC during monitoring.
methods299 paediatric/adult patients with liver disease were analysed; 215 had confirmed WD (Leipzig score ≥ 4). Clinical data, parameters of copper metabolism and liver function tests were collected. REC was analysed in the full cohort. CuEXC was evaluated longitudinally at three standardized timepoints over 12 months in treated adult WD patients and compared with 24-h urinary copper excretion (UCE) after 48-h treatment interruption.
resultsREC demonstrated excellent diagnostic accuracy with an AUC of 0.955 (sensitivity 88.4%, specificity 91.7%). In adult ALF, REC perfectly discriminated WD (n = 2/2, 100%) from other causes. CuEXC declined significantly in therapy-naïve patients and differentiated these from very stable patients, but showed limited discrimination between stable versus unstable patients during median follow-up. UCE off-treatment showed parallel trajectories to CuEXC.
conclusionsREC is a highly accurate diagnostic biomarker for WD, including adult ALF. CuEXC is useful to characterize initial treatment response and copper control, but its role as a routine monitoring biomarker between stable and unstable patients remains uncertain and requires prospective validation, whereas UCE remains as a robust follow-up parameter in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.